RaQualia looks to progress lead EP4 inhibitor on back of Aratana deal
This article was originally published in Scrip
Pfizer Japan spin-out RaQualia Pharma expects a new active pharmaceutical ingredient (API) development agreement with the private US firm Aratana Therapeutics to help progress the development of one of its most advanced pipeline candidates.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.